Fox Run Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Fox Run Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$518K	Buy	26,590 +10,072	+61%	+$183K	0.09%	463
2026 Q1	$280K	Sell	16,518 -55,444	-77%	-$918K	0.05%	645
2025 Q4	$948K	Buy	71,962 +60,562	+531%	+$715K	0.15%	234
2025 Q3	$81.7K	Buy	+11,400	New	+$594K	0.01%	871
2024 Q1	–	Sell	-5,398	Closed	-$326K	–	960
2023 Q4	$326K	Buy	+5,398	New	+$278K	0.08%	463

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fox Run Management's MLTX Position: Q2 2026 in Review

Fox Run Management increased its MoonLake Immunotherapeutics (MLTX) stake by 61% in Q2 2026, buying an estimated $183K and bringing the position to 26,590 shares worth $518K. The position accounts for 0.09% of the portfolio, ranked #463.

Fox Run Management first reported a position in MLTX in Q4 2023 and has held it in 5 quarters since. The position peaked at $948K in Q4 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Fox Run Management held 26,590 shares of MoonLake Immunotherapeutics worth $518K as of Q2 2026.
Fox Run Management bought 10,072 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $183K.
MoonLake Immunotherapeutics made up 0.09% of Fox Run Management's portfolio in Q2 2026, its #463 holding.
Fox Run Management first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 5 quarters since.
Fox Run Management's MoonLake Immunotherapeutics position peaked at $948K in Q4 2025.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.